Your account is not claimed yet. You can sign up with ORCID to claim your account.

Laura Lynn Kovanda (Laura Kovanda, Laura L Kovanda)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 18

Top Venues

Antimicrobial agents and chemotherapy

Scientific reports

Pharmaceuticals (Basel, Switzerland)

Journal of pharmacokinetics and pharmacodynamics

Astellas Pharma Global Development Inc

University of Liverpool (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Astellas Pharma Global Development Inc Nov 12o 1997

United States

Senior Director, Global Development

Education History

University of Liverpool

United Kingdom

PHD

Publications

Domenico Umberto De Rose, Iliana Bersani, Maria Paola Ronchetti, Fiammetta Piersigilli, Sara Cairoli, Andrea Dotta, Amit Desai, Laura Lynn Kovanda, Bianca Maria Goffredo, Cinzia Auriti
Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Domenico Umberto De Rose, Iliana Bersani, Maria Paola Ronchetti, Fiammetta Piersigilli, Sara Cairoli, Andrea Dotta, Amit Desai, Laura Lynn Kovanda, Bianca Maria Goffredo, Cinzia Auriti
Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Kamal A Hamed, Marc Engelhardt, Laura Lynn Kovanda, Jin Ju Huang, Jean Yan, Jalal A Aram
Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies. Scientific reports 13 (1) (2023)
Domenico Umberto De Rose, Iliana Bersani, Maria Paola Ronchetti, Fiammetta Piersigilli, Sara Cairoli, Andrea Dotta, Amit Desai, Laura Lynn Kovanda, Bianca Maria Goffredo, Cinzia Auriti
Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies. Pharmaceuticals (Basel, Switzerland) 16 (3) (2023)
Laura Lynn Kovanda, Gabriele Sass, Marife Martinez, Karl V Clemons, Hasan Nazik, Therese M Kitt, Nathan P Wiederhold, William W Hope, David A Stevens
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of Coccidioidomycosis. Antimicrobial agents and chemotherapy 65 (6) (2021)
Laura Lynn Kovanda, Sean M Sullivan, Larry R Smith, Amit V Desai, Pete L Bonate, William W Hope
Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects. Antimicrobial agents and chemotherapy 63 (6) (2019)
Laura Lynn Kovanda, Charles Giamberardino, Laura McEntee, Dena L Toffaletti, Kelly S Franke, Andrew Bartuska, Gordon Smilnak, George C de Castro, Katelyn Ripple, William W Hope, John R Perfect
Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis. Antimicrobial agents and chemotherapy 63 (9) (2019)
Michael A Pfaller, Paul R Rhomberg, Nathan P Wiederhold, Connie Gibas, Carmita Sanders, Hongxin Fan, James Mele, Laura Lynn Kovanda, Mariana Castanheira
In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. Antimicrobial agents and chemotherapy 62 (10) (2018)
David Andes, Laura Lynn Kovanda, A Desai, Therese Kitt, M Zhao, Thomas J Walsh
Isavuconazole Concentration in Real-World Practice: Consistency with Results from Clinical Trials. Antimicrobial agents and chemotherapy 62 (7) (2018)
David R Andes, Mahmoud A Ghannoum, Pranab K Mukherjee, Laura Lynn Kovanda, Qiaoyang Lu, Mark E Jones, Anne Santerre Henriksen, Christopher Lademacher, William W Hope
Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Antimicrobial agents and chemotherapy 63 (1) (2018)
Laura Lynn Kovanda, Amit V Desai, William W Hope
Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis. Journal of pharmacokinetics and pharmacodynamics 44 (2) (2017)
Laura Lynn Kovanda, Francisco M Marty, Johan Maertens, Amit V Desai, Christopher Lademacher, Marc Engelhardt, Qiaoyang Lu, William W Hope
Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. Antimicrobial agents and chemotherapy 61 (6) (2017)
Amit V Desai, Laura Lynn Kovanda, William W Hope, David Andes, Johan W Mouton, Donna L Kowalski, Robert W Townsend, Salim Mujais, Peter L Bonate
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi. Antimicrobial agents and chemotherapy 61 (12) (2017)
Vidmantas Petraitis, Ruta Petraitiene, Matthew W McCarthy, Laura Lynn Kovanda, Myo H Zaw, Kaiser Hussain, Naima Shaikh, Bo Bo W Maung, Navjot K Sekhon, William W Hope, Thomas J Walsh
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial agents and chemotherapy 61 (9) (2017)
Emily Larkin, Christopher Hager, Jyotsna Chandra, Pranab K Mukherjee, Mauricio Retuerto, Iman Salem, Lisa Long, Nancy Isham, Laura Lynn Kovanda, Katyna Borroto-Esoda, Steve Wring, David Angulo, Mahmoud Ghannoum
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrobial agents and chemotherapy 61 (5) (2017)
Teclegiorgis Gebremariam, Sondus Alkhazraji, Clara Baldin, Laura Lynn Kovanda, Nathan P Wiederhold, Ashraf S Ibrahim
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis. Antimicrobial agents and chemotherapy 61 (5) (2017)

Laura Lynn Kovanda.css-eqlu8i{font-size:small;padding-left:4px;} (Laura Kovanda, Laura L Kovanda)

Publication Activity (10 Years)

Top Topics

Top Venues

Laura Lynn Kovanda (Laura Kovanda, Laura L Kovanda)